Synergy Pharmaceuticals (NASDAQ:SGYP) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.01), MarketWatch Earnings reports. The business had revenue of $11.11 million for the quarter, compared to the consensus estimate of $15.65 million.
Shares of NASDAQ:SGYP traded down $0.09 during midday trading on Friday, hitting $0.36. 9,599,730 shares of the company’s stock traded hands, compared to its average volume of 7,622,059. The firm has a market capitalization of $114.13 million, a price-to-earnings ratio of -0.35 and a beta of 2.38. Synergy Pharmaceuticals has a twelve month low of $0.35 and a twelve month high of $3.10.
Several research firms recently weighed in on SGYP. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Synergy Pharmaceuticals in a report on Tuesday, August 7th. Zacks Investment Research upgraded shares of Synergy Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a report on Tuesday, August 14th. BidaskClub lowered shares of Synergy Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, September 12th. Canaccord Genuity lowered shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 26th. Finally, BTIG Research lowered shares of Synergy Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Friday, October 26th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the stock. Synergy Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $8.17.
Synergy Pharmaceuticals Company Profile
Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome.
Featured Story: Fiduciary
Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.